Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
The graft versus host disease treatment market is expected to grow with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are increasing demand for personalized medicine, growing geriatric population, and surge in number of hematopoietic stem cell transplantation and solid organ transplantations across the globe.
The future of the market looks promising with opportunities in the hospital pharmacy, online pharmacy, and retail pharmacy markets. This study includes a forecast for the global graft versus host disease treatment by product, disease type, end use, and region.
Graft Versus Host Disease Treatment Market by Product [Shipment Analysis by Value from 2018 to 2030]:
- Corticosteroids
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- Others
Graft Versus Host Disease Treatment Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:
- Acute Graft-Versus-Host Disease
- Chronic Graft-Versus-Host Disease
Graft Versus Host Disease Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Others
Graft Versus Host Disease Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Graft Versus Host Disease Treatment Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies graft versus host disease treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the graft versus host disease treatment companies profiled in this report include:
- Pfizer
- Sanofi
- Astellas Pharma
- Incyte
- AbbVie
- Bristol Myers Squibb
- Sanofi
Graft Versus Host Disease Treatment Market Insights
- Corticosteroid is expected to witness the highest growth over the forecast period due to rising burden of target disease and growing number of research studies.
- Within this market, hospital pharmacies will remain the largest segment due to availability of wide variety of treatment options and personalized counseling.
- North America will remain the largest region over the forecast period due to presence of advanced healthcare infrastructure and increasing number of transplants in this region.
Features of the Graft Versus Host Disease Treatment Market
- Market Size Estimates: Graft versus host disease treatment market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Graft versus host disease treatment market size by product, disease type, end use, and region in terms of value ($B).
- Regional Analysis: Graft versus host disease treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different products, disease types, end uses, and regions for the graft versus host disease treatment market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the graft versus host disease treatment market.
- Analysis of competitive intensity of the industry based on Porter's Five Forces model.
For more information about this report visit https://www.researchandmarkets.com/r/3xpju7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.